Vaccine Blurbs Issue 175: Renew Your Agreement Before It Expires!


Washington State Department of Health | March 28, 2023

Some Counties are Due to Renew Agreements by March 31st

Some providers enrolled in the Childhood Vaccine Program are required to renew their provider agreement by the end of March. Please check out the Renewal Schedule to see if your clinic is located in one of these counties. If you are due to renew your provider agreement in March, and it isn't complete by this Friday, March 31st, 2023, your clinic will no longer be allowed to order childhood vaccines until your 2023 agreement has been approved. Please submit your 2023 provider agreement today to avoid an interruption in your vaccine ordering privileges.

2023 renewal schedule

Practice Profile Tips for Your Provider Agreement Renewal

Provider Support Specialists with the Childhood Vaccine Program are busy reviewing Provider Agreement renewals for 2023 and noticing that the practice profile page in the agreement may be causing confusion. On page 3 in the provider agreement, you are required to enter the number of children who received publicly supplied vaccines in your clinic in the previous calendar year by age group and eligibility/insurance status. This data can be collected in a variety of ways, either working with your billing department to generate this data, or by running the VFC Profile Report in the IIS. Keep in mind that when you are renewing your agreement, the previous year's data will auto-populate the page, so you need to update it with 2022 data. If it's not updated, we will return the agreement to you for updates. Please ensure that when you submit your provider agreement for approval, that your practice profile data has been updated with 2022 data. Use the Provider Agreement Renewal Guide to assist you with the renewal process.

practice profile instructions

CVP Training Series

Join us Thursday, April 20, 2023 for the next session in the monthly CVP Training Series. This session will give an overview of vaccine choice and review the vaccine ordering process. Vaccine choice is the window of time twice per year when a provider has the opportunity to switch their preferred vaccine brands in their order set. Our Immunization Nurse Consultant will also cover new vaccines recently approved, considerations for using these vaccines in your practice, and share available clinical resources. Please join us to learn more! You can also find previously recorded sessions in the CVP Training Series on our webpage.

Upcoming CVP training

Helpful Hints

Read Your IIS Messages Regularly

Did you know you can see messages in the IIS that your Provider Support Specialist has sent you? Often times these messages are followed up with a typical email, but you can also see messages directly in the IIS if your Provider Support Specialist is trying to reach you. For example, you may see messages requesting additional accountability reports that may be missing in order to approve a vaccine order or vaccine transfer. You may also see messages if your provider agreement is returned for updates or is approved or expired. To view these messages, use this guide.

IIS messages

Clinical Corner

HPV Letter for Providers from DOH

Dr. Umair A. Shah, Washington State Department of Health Secretary of Health, sent a letter to providers regarding starting HPV vaccine at nine years old. Please review the letter and continue to recommend and administer HPV vaccine at age nine.

FDA approves intramuscular injection in addition to subcutaneous administration for M-M-R II, Varivax, and ProQuad vaccines

The Food and Drug Administration (FDA) approved intramuscular (IM) injection as an option for the following Merck vaccines: M-M-R II (measles-mumps-rubella vaccine), Varivax (varicella vaccine), and ProQuad (measles-mumps-rubella-varicella vaccine). Previously, these vaccines were only licensed for subcutaneous injection.  Two brands of MMR vaccine are available in the United States. Only Merck’s brand is licensed for either IM or subcutaneous administration. Priorix from GSK is licensed only for subcutaneous administration. References:

CDC updates and expands testing recommendations for hepatitis B virus infection

CDC recently published Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations—United States, 2023The report updates previous guidelines, now recommending that all adults be screened for hepatitis B infection with a triple-panel test at least once in their lifetimes. The new guidelines also recommend that people who are not vaccinated for hepatitis B, but are at increased risk of infection, receive testing.  Risk-based testing is recommended for:

  • People incarcerated or formerly incarcerated in a jail, prison, or other detention setting
  • People with a history of sexually transmitted infections or multiple sex partners
  • People with a history of hepatitis C virus infection

Anyone can be infected with hepatitis B. Because risk may be short term or not recognized, all adults can benefit from knowing their status and being protected from infection. Anyone who requests testing should receive it. In addition to screening, CDC recommends vaccination of all people younger than age 60 years and all people age 60 or older at increased risk. Anyone age 60 or older may be vaccinated.   A person who is unvaccinated may have blood drawn for screening, followed by the first dose of vaccine at the same visit. If vaccination is indicated, it should not be delayed if screening is not feasible. Another resource is from the Hepatitis B Foundation: Call to Action: Eliminating HBV through Universal Screening and Vaccination

For questions about the immunization schedule, the Immunization Information System forecast, or any other immunization clinical questions, please send an email to Check out the Immunization Training web page for more resources and training opportunities.